Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics is supported by a strengthening commercial base, with 1Q26 revenues of approximately $165M, cash and short-term marketable securities of $338M, and management expecting a return to profitability in 2Q26 as Korlym’s pharmacy transition clears and record patient starts signal a recovery. Its growth outlook is further improved by Lifyorli’s rapid uptake after approval, including more than 200 unique prescribers in April and a guidance increase to a $1B midpoint for FY2026, suggesting a credible move toward a multi-product franchise. The pipeline adds significant optionality, as relacorilant showed meaningful benefit in ROSELLA for platinum-resistant ovarian cancer and may support a Class II NDA resubmission for Cushing’s syndrome, reinforcing the company’s expanding oncology and endocrine opportunity.

Corcept Therapeutics is vulnerable to a valuation reset because the stock’s implied upside depends heavily on long-dated projections through 2034, which leaves the thesis exposed if revenue or earnings fail to scale as expected. The company’s enterprise value estimate of approximately $12.5B to $21.6B is highly sensitive to a 12% discount rate and aggressive 7.0x sales and 18.0x earnings multiples, while the cited risks span commercial execution, clinical and regulatory setbacks, reimbursement pressure, financial strain, and legal or intellectual property disputes. For a commercial-stage biotech with dependence on Korlym and an uncertain pipeline across multiple indications, that concentration of risk makes the outlook fundamentally fragile.